Innovent Biologics, Inc.
IVBXF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $51,801,956 | $54,460,522 | $44,039,849 | $56,702,099 |
| - Cash | $7,508,185 | $10,052,095 | $1,016,165 | $1,359,408 |
| + Debt | $2,831,043 | $3,620,529 | $3,228,508 | $2,496,926 |
| Enterprise Value | $47,124,814 | $48,028,956 | $46,252,192 | $57,839,617 |
| Revenue | $9,421,888 | $6,206,070 | $4,556,380 | $4,269,729 |
| % Growth | 51.8% | 36.2% | 6.7% | – |
| Gross Profit | $7,911,678 | $4,399,226 | $3,625,390 | $3,696,689 |
| % Margin | 84% | 70.9% | 79.6% | 86.6% |
| EBITDA | -$480,277 | -$660,684 | -$1,749,349 | -$2,374,506 |
| % Margin | -5.1% | -10.6% | -38.4% | -55.6% |
| Net Income | -$94,631 | -$1,027,913 | -$2,179,270 | -$2,728,755 |
| % Margin | -1% | -16.6% | -47.8% | -63.9% |
| EPS Diluted | -0.056 | -0.66 | -1.46 | -1.88 |
| % Growth | 91.5% | 54.8% | 22.3% | – |
| Operating Cash Flow | $1,287,024 | $147,810 | -$1,918,804 | -$2,024,843 |
| Capital Expenditures | -$1,705,412 | -$1,383,460 | -$1,381,730 | -$1,847,516 |
| Free Cash Flow | -$418,388 | -$1,235,650 | -$3,300,534 | -$3,872,359 |